TELA Bio (TELA) Asset Writedowns and Impairment (2018 - 2026)

TELA Bio has reported Asset Writedowns and Impairment for 9 years, with the latest figure at $298000.0 in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 6.43% year-over-year to $298000.0 in Q2 2026; TTM through Jun 2026 was $2.7 million, a 9.27% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 20.14% from the prior year.
• Asset Writedowns and Impairment was $298000.0 for Q2 2026 at TELA Bio, down from $935000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $1.4 million in Q4 2024, with the low at $57000.0 in Q4 2022.
• Average Asset Writedowns and Impairment over 5 years is $546000.0, with a median of $568000.0 recorded in 2023.
• The largest YoY upside for Asset Writedowns and Impairment was 640.35% in 2023 against a maximum downside of 63.22% in 2023.
• Over 5 years, Asset Writedowns and Impairment stood at $57000.0 in 2022, then soared by 640.35% to $422000.0 in 2023, then soared by 229.86% to $1.4 million in 2024, then slumped by 41.24% to $818000.0 in 2025, then plunged by 63.57% to $298000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $298000.0 (Q2 2026), $935000.0 (Q1 2026), and $818000.0 (Q4 2025), per Business Quant data.